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ABSTRACT
Objectives: In recent years, large-scale longitudinal
neuroimaging studies have improved our understanding
of healthy ageing and pathologies including Alzheimer’s
disease (AD). A particular focus of these studies is group
differences and identification of participants at risk of
deteriorating to a worse diagnosis. For this, statistical
analysis using linear mixed-effects (LME) models are
used to account for correlated observations from
individuals measured over time. A Bayesian framework
for LME models in AD is introduced in this paper to
provide additional insight often not found in current LME
volumetric analyses.
Setting and participants: Longitudinal neuroimaging
case study of ageing was analysed in this research on
260 participants diagnosed as either healthy controls
(HC), mild cognitive impaired (MCI) or AD. Bayesian LME
models for the ventricle and hippocampus regions were
used to: (1) estimate how the volumes of these regions
change over time by diagnosis, (2) identify high-risk non-
AD individuals with AD like degeneration and (3)
determine probabilistic trajectories of diagnosis groups
over age.
Results:We observed (1) large differences in the
average rate of change of volume for the ventricle and
hippocampus regions between diagnosis groups, (2)
high-risk individuals who had progressed from HC to
MCI and displayed similar rates of deterioration as AD
counterparts, and (3) critical time points which indicate
where deterioration of regions begins to diverge between
the diagnosis groups.
Conclusions: To the best of our knowledge, this is the
first application of Bayesian LME models to
neuroimaging data which provides inference on a
population and individual level in the AD field. The
application of a Bayesian LME framework allows for
additional information to be extracted from longitudinal
studies. This provides health professionals with valuable
information of neurodegeneration stages, and a potential
to provide a better understanding of disease pathology.
INTRODUCTION
Alzheimer’s disease (AD) is the most
common form of dementia worldwide.1
Advances of neuroimaging techniques have
been useful for early diagnosis of neurode-
generative disorders2 3 and, coupled with
mathematical and statistical models, provide
insight to better understand healthy ageing
and disease pathology degeneration.4–6 The
use of linear mixed-effects (LME) models
has been advocated by Bernal-Rusiel et al7
and, recently, by Ziegler et al8 to characterise
longitudinal degeneration from neuroima-
ging data. Bayesian LME (BLME) models are
applied in this research to provide insight
into the diagnosis of AD over time. In this
research, we address three main areas: popu-
lation diagnosis comparisons based on esti-
mated volumetric rate of change over age,
ranking of participants by order of linear
volumetric rate of change and region-speciﬁc
probability trajectories across age of diagno-
sis groups, conditional on prevalence rates.
Recent state-of-the-art analysis on clinical
diagnosis classiﬁcation groups emphasises
Strengths and limitations of this study
▪ The models presented in this research address
realistic challenges in a longitudinal study setting
such as: large patient drop-out (unbalanced
design), large and small diagnosis groups and
noisy MRI observations.
▪ This is the first study of its kind to incorporate
data external to this analysis, in terms of preva-
lence rates, in conjunction with the statistical
models to infer disease trajectories for brain
regions over age.
▪ This research does not accommodate partici-
pants with other neurological disorders and
assumes that participants are in one of three
groups: healthy control, mild cognitive impaired
and Alzheimer’s disease.
▪ Additional covariates which are known to affect
neurodegeneration were not included in this ana-
lysis, such as gender and genetic status.
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the need to better understand disease pathology in
asymptomatic and early stages of individuals with
AD.9–13 A strong focus of longitudinal neuroimaging
studies is to monitor morphological changes among
healthy control (HC), mild cognitive impaired (MCI)
and AD groups as they progress throughout the disease
continuum.7 14
Previous LME models of volumetric degeneration
reported on comparisons assessing ranking of diagnosis
levels.7 15 However, in these studies, the magnitude of
the differences of disease progression as well as their
estimated variances is often excluded;7 14–17 thus, a
richer insight into the differences of diagnosis levels is
lacking. The BLME approach uses simulation techniques
to draw from the posterior distribution, which is a com-
bination of prior information and information from the
data (through the likelihood function), to provide diag-
nosis group estimates and comparisons. These simula-
tions quantify uncertainty and provide posterior
probabilities that can be compared directly, without
referring to signiﬁcance levels or multiple statistical
tests.
The development of methods which account for large
intervariability and intravariability of biomarkers pre-
sents a challenge in longitudinal neuroimaging
studies.18–20 Furthermore, the observations of diagnosis
group tends to become unbalanced over time, which
makes it difﬁcult to deduce information of the complex
AD pathway. However, insight into neurodegeneration of
high-risk participants, namely MCI, is crucial for early
detection methods and improving diagnostic accuracy of
AD.5 21 Several authors such as Harville and
Carriquiry,22 Gelman and Hill23 and Li et al24 state that
BLME models have the capability to seamlessly handle
unbalanced data and small-sample design analysis. This
motivates our choice of statistical framework, as we aim
to use as much information as possible from the study
analysed and retain participants with a single
observation.
Individuals in order of neurodegeneration severity
allow for comparisons of progression of all individuals
over the study, while quantifying the uncertainty and
estimating variability of individualised conversion rates.
The application of BLME models allows for estimation
of class membership probabilities and estimation of
deterioration rates of each participant via the analysis of
random effects. This type of analysis is often overlooked
in longitudinal studies of ageing.25
Since the ﬁeld of neuroimaging in AD has been
rapidly expanding in the past 20 years,18 26–28 it is of
interest to incorporate as much relevant information as
possible, as independent longitudinal neuroimaging
studies often build on and support each other.5 8 29 This
can be achieved using the Bayesian approach, as it com-
bines external information with experimental data at
hand, while accounting for various sources of uncer-
tainty. This background information can often be incor-
porated in the form of the prior, but it can also be
applied after estimation of the model to provide add-
itional inference from our model outcomes. In the
current project, we demonstrate this concept by combin-
ing model information with prior knowledge obtained
from prevalence studies to formulate probabilistic diag-
nosis group trajectories over age.
Jack et al30 highlight the importance of population fre-
quency or probabilistic trajectories of neurodegenera-
tion groups over a wide age span. Their study quantiﬁed
frequencies of expected neurodegeneration cases
dependent on ages 50–89. Particular focus was placed
on asymptomatic individuals (preclinical AD) who were
at risk of developing AD and ages of increased frequency
of convergence to AD as they reach their later years.
While our methods can also be used for similar pur-
poses and place emphasis on a particular neurodegen-
eration group, the goal for our ﬁnal analysis is to
identify critical time points where all diagnosis levels
begin to diverge. This can aid in discovering groups or
patterns in neurodegeneration consistent with healthy
ageing or the AD pathway. Alternatively, a similar analysis
can also be used to compare diagnosis trajectories of dif-
ferent longitudinal neuroimaging population studies,
such as the Alzheimer’s Disease Neuroimaging Initiative
(ADNI).
This paper is outlined as follows. The AIBL longitu-
dinal study of ageing section describes the case study.
The How do HC, MCI and AD participants degenerate
over time? sections show an application of the BLME
models to address multiple comparisons of various sizes
from baseline diagnosis, including large (NHC ¼ 168
people) and small groups (NMCI ¼ 50 and NAD ¼ 42
people at baseline). The How to identify individuals
with high levels of neurodegeneration? sections rank
individuals by order of neurodegeneration severity,
thereby comparing the progression of all individuals
over the study time. Approximately 10% of individuals
convert from a baseline case to a worse diagnosis
throughout the length of the study. This analysis allows
for the identiﬁcation of those participants who are most
at risk of developing AD like rates of deterioration for
the hippocampus and ventricle regions of the brain.
The third and ﬁnal area addressed in this research is
presented in the How do diagnosis trajectories vary over
age? sections, which estimates probabilistic diagnosis
group trajectories across age, derived from neuroima-
ging information. This requires the synthesis of informa-
tion from the study cohort and the AD literature.
AIBL LONGITUDINAL STUDY OF AGEING
The neuroimaging data analysed in this paper were
obtained from the Australian Imaging Biomarker and
Lifestyle Study of Ageing (AIBL). This is an ongoing
study which aims to discover which biomarkers such as
cognitive assessment results, neuroimaging, lifestyle and
demographic factors potentially inﬂuence subsequent
development of AD. The sample comprises N ¼ 260
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people, who have at most four repeated observations
∼18 months apart. These data are highly unbalanced,
since patient drop-out occurs at every time point
throughout the study, with ∼69% of participants in the
ﬁnal follow-up.
Key regions of the brain which are strongly associated
with neurodegeneration in relation to AD and healthy
ageing include the lateral ventricles31 32 and hippocam-
pus volumes.3 15 33–35 Atrophy due to disease pathology
spreads throughout particular regions such as the hippo-
campus, which leads to a general decrease in volume
over time. The decrease in brain matter results in an
increase in cerebrospinal ﬂuid (CSF) which bathes and
cushions the brain and spinal cord. The lateral ventricles
are ﬁlled with CSF; hence, an increase in overall brain
atrophy results in an increase in ventricle volume.
Models presented here were considered separately for
the lateral ventricles and the sum of the left and right
hippocampal (hippocampus) volumes derived from
MRI. See Rowe et al36 for details on image acquisition
and processing. While we cannot deduce entire brain
neurodegeneration inferences from the analysis of two
regions, in this research we discuss in detail the applica-
tion of two well-known AD-related regions and note that
the BLME models presented here can be easily applied
to any other region of interest.
Brain region volumes were normalised by the intracra-
nial volume (ICV); hence, all volumes are in the (0, 1)
interval. This accounts for the variability of different
cranial sizes, while preserving the trend in volume.37 38
Owing to the wide range in values and in order to elim-
inate numerical problems in the estimation of these
models, age was standardised (age age)=sd(age),
where age and sd(age) are the empirical mean and
standard deviations of the study group ages. Likewise,
the hippocampus ICV response was scaled up by a factor
of 100, in order to avoid variance estimates close to 0
which can be difﬁcult to estimate. All participants in this
study were categorised as: HC, MCI and those with a
probable diagnosis of AD at each time point based on
neuropsychological diagnosis. The aim of the BLME
models was to capture the linear decrease in regional
brain volume across ages for people within three diagno-
sis groups.
METHODS
LME models are a standard approach to modelling
repeated observations from several individuals.39
Standard LME models require the following assump-
tions to be met: a linear relationship exists between the
response and the explanatory variables; the terms at
every level are Gaussian, although for non-normal
models we may extend this assumption to the exponen-
tial family and apply generalised linear mixed models;40
the variances across all levels are homoscedastic, and
repeated observations for an individual can be corre-
lated, but observations between people are assumed to
be independent. The general LME model is of the fol-
lowing form:
y ¼ Xbþ Zbþ 1 ð1Þ
where X and Z denote the design matrices, and vectors
b and b are the ﬁxed and random effects, respectively,
for r ﬁxed, m random effects and a total sample size of
n observations. The residual vector 1 is assumed to be
normally distributed with 1  MVN(0; s2In), where In
is the n n identity matrix. While our response values
are constrained to the (0, 1) range, the assumptions of
the model were assessed via a histogram of the residuals,
scatter and quantile–quantile plots and were found to
not deviate from our model assumptions (refer to the
online supplementary material). The parameters in this
analysis are in the volume ICV/standard age unit and
careful back transformation is required to convert to an
alternative unit, such as mm3/year. The random-effects
vector b is assumed to be multivariate normally distribu-
ted, b  MVN(0; S), where the variance–covariance
matrix of the random effects is denoted by Σ.
Statistical analysis
In a Bayesian framework, the likelihood corresponding
to the model in equation (1) is pðyjb; X; Z; b; s2;SÞ,
which is conditional on the random effects and on the
model parameters. The resultant joint posterior distribu-
tion for the model parameters and random effects given
in the data is
pðb; b; s2;SjX; Z; yÞap(yjb; X; Z; b; s2;S)
p(b;S) p(b) p(s2) p(S):
ð2Þ
In the absence of external information, weakly inform-
ative priors, p(b); p(s2) and p(S), were used through-
out (refer to equation (3) in the BLME in the context
of the case study section for full speciﬁcation of priors).
Under the Bayesian paradigm, all the assumptions stated
in the Methods section remain. Furthermore, as Gelman
et al41 and Gelman and Hill23 state, additional complex-
ity and generalisation of the LME model comes naturally
under the Bayesian framework.
Estimation of the model parameters was achieved by
sampling from the joint posterior distribution using
Markov chain Monte Carlo (MCMC) techniques42 which
samples from the marginal posterior distributions as a
by-product. Note that the parameter estimates are
obtained by integrating over the posterior distribution,
rather than maximising the likelihood, as numerical
methods to solve integrals in high dimensions are often
difﬁcult to compute.42 43
BLME in the context of the case study
Following equation (1), the normalised volume is
denoted by Yij for the ith individual at the jth time point,
where binary values xMCI and xAD refer to the two levels
of diagnosis, MCI and AD, respectively, with HC as the
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baseline. The BLME model for person i = 1, 2, ..., 260
at time point j ¼ 1; 2; 3; 4 is given by
Yijj mij; s2  N(mij; s2) ð3Þ
mij¼ b0iþ b1xMCI; ijþ b2xAD; ijþb3iStndAgeijþ
b4iStndAgeijxMCI; ij þ b5iStndAgeijxAD; ij
bki¼ bkþ bki; for k ¼ 0; 3; 4; 5
bi  MVN(0; S): ð3Þ
Random effects bi¼[b0i; b3i; b4i; b5i] denote the ith
individuals deviation from population means b0; b3; b4
and b5. The model in equation (3) allows for correlation
between random effects and this is reﬂected by
the structure of the priors. The variance of the residual
and the variance–covariance matrices are designated
by semiconjugate priors s2  IG(0:001; 0:001) and
S  Wishart(R; 6), respectively, where ¼ 1000 I4. The
ﬁxed-effects vector b ¼ [b0;b1;b2;b3;b4;b5]T is
assumed to be normal with b  MVN(0; 1e6; I6).
Non-linear trends in age were investigated in order to
derive an appropriate model for our application (refer to
the online supplementary material for further details).
However, the linear predictor in equation (3) was found
to approximately represent the data. Posterior predictive
plots were used as a measure of goodness-of-ﬁt. This
involved simulating from the posterior distribution and
forming 95% credible intervals of the posterior predictive
responses, which were compared with the observed
responses.
The R software was used to implement the Bayesian
models.44 The rjags package45 implemented MCMC
methods to estimate the parameters. Packages coda45 and
ggplot246 were used to analyse the MCMC chains and visu-
alise the three sets of analyses presented here. All R source
code for this manuscript and simulated data is available at
github website https://github.com/MarcelaCespedes/
Bayesian_inference_on_neuroimaging.
Two independent MCMC runs were performed using
different starting values; each chain ran for 300K itera-
tions of which 100K were discarded as burn-in and the
remaining simulations were thinned at every 50th iter-
ation. The retained 8000 simulations were taken as
samples from the posterior distribution. Convergence
diagnostics of the chains included observing the trace,
density and autocorrelation plots as well as the Gelman
and Rubin47 diagnostic. Desirable chain mixing and con-
vergence was observed in all diagnostics. In addition to
the residual and posterior checks, leave-one-out cross-
validation (LOOCV) was performed to assess the
model’s predictive capability of new data, and the mean
squared error (MSE) was computed on both models. In
a hierarchical setting, the size of the data and how
balanced the structure is heavily affects the relative per-
formance of the model.48 For this reason, we performed
two approaches for LOOCV on the ventricle and hippo-
campus models. First, all the observations for an
individual were omitted from the analysis (and, there-
fore, all of their data), and this was repeated for all indi-
viduals. Second, for those participants with more than
one observation (199 participants in our data set), a
single observation was randomly removed from the ana-
lysis (refer to the online supplementary material for full
results). In practice, we wish to minimise the MSE, as it
comprises the sum of the variance, bias squared and
irreducible error. Both LOOCV approaches demon-
strated low MSE values, which support our model choice
(refer to the online supplementary material for full
details).
For comparison, the research questions addressed
here were attempted with the model in equation (3)
ﬁtted in the classical framework for both regions. The
How do diagnosis trajectories vary over age? and How to
identify individuals with high levels of neurodegenera-
tion? sections discuss the results for each analysis.
M: How do HC, MCI and AD participants degenerate over
time?
Performing a Bayesian analysis provides a posterior dis-
tribution of the parameter which can be used here to
estimate the rate of volumetric degeneration for each
diagnosis level.16 In this analysis, we estimate a diagnosis
group effect via the posterior mean of the relevant par-
ameter, and investigate differences in these effects via
credible intervals (about differences of these means).
Other than mean diagnosis comparisons, further ana-
lysis in terms of mean differences of these groups is
often not performed in LME volumetric neuroimaging
models.7 49 However, as highlighted in Apostolova et al31
and Holland et al,15 such insight allows for potential
techniques to detect signs of AD like neurodegeneration
on presymptomatic individuals.
As indicated in equation (3), the population rate of
deterioration for each diagnosis consists of the addition
of the baseline effect (HC) with the interaction terms
for the other diagnosis groups (MCI or AD). Thus, the
posterior marginal distributions of b3 for the baseline,
b3 þ b4; b3 þ b5, for MCI and AD diagnosis, respect-
ively, were compared.
Furthermore, the order of deterioration of the diagno-
sis levels over both brain regions was assessed. Posterior
probabilities were used to order parameter values, since
this allows for direct probabilistic diagnosis group com-
parisons based on the MCMC output while quantifying
uncertainty in the parameter estimates. Let M be the
number of MCMC posterior draws; in our methods,
M=8000 as described in the BLME in the context of the
case study section.
The probability that the rate of change for MCI
degeneration is smaller than an AD diagnosis for the
ventricle region is estimated by
P(MCI , AD) ¼ 1
M
XM
m¼1
1ðbm4  bm5 , 0Þ; ð4Þ
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where the indicator function 1 is equal to 1 if bm4  bm5
<0 and 0 otherwise. Probabilities for other comparisons
of diagnosis levels for the ventricle and hippocampus
regions are computed in a similar manner; see the
R: How do HC, MCI and AD participants degenerate
over time? section for full results.
R: How to identify individuals with high levels of
neurodegeneration?
It is expected that individuals who are healthy (HC) will
have relatively minimal deterioration while those with
MCI or AD will show increasing levels of deterioration.
Hence, we would expect that the volumetric rate of
change will reﬂect the neuropsychological clinical diag-
nosis. However, as noted by Woolrich et al,50
Bernal-Rusiel et al7 and Bernal-Rusiel et al,51 high inter-
variability and intravariability is often observed in longi-
tudinal neuroimaging studies. For this reason, in this
analysis we foresee the estimated volumetric rate of
change for a few individuals not to group with partici-
pants of the same diagnosis and exercise caution when
comparing estimated trajectories of individuals with a
single observation.
Participants with outlier rates of deterioration or not
within range of their diagnosis levels, as well as those
who converted throughout the study, are of particular
interest as they do not conform to the overall trend over
time ordering. Thus, a question of interest might be: If
an individual has a high neurodegeneration rate with
respect to their corresponding diagnosis group, are they
likely to degenerate along the AD pathway?
In our data, 1 individual progressed directly from HC
to AD, 2 were observed to follow the full spectrum (HC
to MCI to AD throughout all 4 follow-ups), 8 people pro-
gressed from HC to MCI and a further 16 individuals
progressed from MCI to AD. These converters can be
tracked to observe their severity with respect to the rest
of the cohort. In this section, particular focus is on the
converters who progressed from HC to MCI, and the
comparison of their estimated rates of deterioration with
AD participants, as they could be potential AD conver-
ters and estimate their probability of remaining in such
a high rank.
Unlike our ﬁrst analysis, which compared the esti-
mated population effect across all diagnosis levels, the
focus here is on an individual’s rate of deterioration.
The marginal posterior distributions of individual
random-effects values in the HC (b3i), MCI (b3i þ b4i)
and AD (b3i þ b5i) groups are inspected, to estimate
the rate of deterioration for i ¼ 1; 2; . . . ; 260 indivi-
duals on all four time points.
Furthermore, as discussed in the R: How to identify
individuals with high levels of neurodegeneration?
section and shown in the ordered box plots, the median
rankings of participants and illustrate the large variation
between individuals. Distribution of ranks on partici-
pants takes into account the high variation between indi-
viduals, by ranking participants at every iteration of the
MCMC simulation of the random effects. This results in
M=8000 simulations on every individual and allows us to
derive probabilistic statements on individuals of interest
remaining in a speciﬁed ranking range, for example, the
top 15th quantile. This analysis was performed on both
a subset of the data, using observations with the ﬁrst
three time points, as well as on the full data (four time
points) to investigate the change of rank probabilities
over time for particular individuals of interest. Such ana-
lysis extends the BLME models to allow for the identiﬁ-
cation of high-risk converters among the participants
analysed. Full results are described in the R: How to
identify individuals with high levels of neurodegenera-
tion? section.
M: How do diagnosis trajectories vary over age?
The ventricle and hippocampus models derived in
equation (3) were used to compute probabilities
P ð jHC ; ageÞ, P ðyjMCI ; ageÞ and P ðyjAD; ageÞ, for a
speciﬁed age with volume range denoted by ~y. Given the
information available on an individual at an early age
and within the limits of our data age span, we seek to
answer: At this early age, for a given volume range, what
is the probability that this new individual will be diag-
nosed as HC, MCI or AD? Moreover, how does this
change as the individual ages? These probabilities are
estimated below.
At a given age for ventricle and hippocampus models
stated in equation (3) with diagnosis levels
Diagnosis ¼ {HC, MCI, AD}, the following holds:
P(ADj~y; age) ¼ P(~yjAD; age)P(ADjage)P3
d¼1 Pð~yjDiagnosisd; ageÞ
P(DiagnosisdjageÞ
ð5Þ
The BLME model estimates P(~yjAD; ageÞ,
P(~yjMCI; ageÞ and P(~yjHC; ageÞ. Since M is the
number of MCMC posterior draws,
P(~yjAD; age) ¼ 1
M
XM
m¼1
1(~ym [ ~y) ð6Þ
where the indicator function 1 is equal to 1 if ~ym [ ~y
and 0 otherwise. This expression is the average number
of predicted values ~ym which fall within ~y. A similar
expression was used for MCI and HC diagnosis levels.
Probabilities P(HCjage), P(MCIjage) and P(ADjage)
were obtained from Ward et al52 and Refshauge and
Kalisch53 for ages 60, 65, 70, 75, 80 and 85. We acknowl-
edged that these are very broad estimates which are gen-
eralised over genders, genetic status and many other
factors which are known to affect prevalence rates.
These prevalence rates also do not take into account
participants who develop other forms of dementia, or
any other neuropsychological disorders. Refer to the
online supplementary material for the full table of prob-
abilities used in this analysis. Similar computations were
performed for the other diagnosis levels, MCI and HC,
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to evaluate related probabilities. Owing to the wide vari-
ability observed in the hippocampus and ventricle
volumes among participants, the volume regions were
divided into four different ranges, ~y, which vary over age
groups. Quantile growth curves discussed in Cole and
Green,54 and Koenker55 highlight the advantages of
algorithms that can estimate non-crossing quantiles
which are monotone increasing over age to reﬂect the
heteroscedasticity often found in biological systems. In
this paper, we used the algorithm discussed in Muggeo
et al,56 as it addresses all of these issues and is available
via R package quantregGrowth. The ~y values of took on
ranges; 75–100th, 50–75th, 25–50th and 15–25th centiles
of observed response values, as shown in ﬁgure 1.
For completeness in our analysis, volume ranges such
as the 5–25th centile were explored. However, there was
very little difference in the probability trajectories
among these volume ranges; hence, we maintained the
15–25th centile range. Furthermore, we wished to avoid
low volume outliers, and place emphasis on the degener-
ating trends present in the majority of the data, for bio-
logically meaningful inferences.
The results from applying equation (5) show probabil-
ity trajectories of an individual being in one of the three
diagnosis levels, across ages 60–85 within the four quan-
tile ranges. The goal for this analysis is to identify critical
time points where diagnosis levels begin to diverge
which can aid in discovering groups or patterns in neu-
rodegeneration consistent with healthy ageing or the AD
pathway. Furthermore, the inﬂuence of covariates
gender and apolipoprotein-E (APOE) was explored by
repeating this analysis on subgroups of male, female,
APOE positive and negative.
A similar analysis cannot be performed with a classical
LME model, as the method of maximation of the likeli-
hood does not allow for the straightforward computa-
tion of probabilities P(HCj~y; age); P(MCIj~y; age) and
P(ADj~y; age). Another drawback of the classical
approach is that it does not lend itself to the incorpor-
ation of relevant additional external data, to further
extend statistical inference.
RESULTS
R: How do HC, MCI and AD participants degenerate over
time?
The atrophy patterns for the ventricle and hippocam-
pus regions described in the AIBL longitudinal study
of ageing section are reﬂected in the results of the
BLME models. A decrease in hippocampus volume
and an increase in ventricle volume is depicted by
the posterior densities for the rates of deterioration
for the two responses as shown in ﬁgure 2. As
expected, this biological pattern across the three
levels of diagnosis is reﬂected in ﬁgure 2 as well as
in tables 1 and 2. The ventricle population estimates
of deterioration show an increase in volume as the
diagnosis progressively worsens and the hippocampus
population estimates of deterioration reﬂect a decreas-
ing negative slope from HC, to MCI and AD. The
overlapping densities are expected as individuals gen-
erally progress gradually in order of deterioration
from HC to MCI to AD. Despite this overlap, there
are distinct differences between the average rate of
volumetric deterioration between the three diagnoses,
as seen in table 1.
Figure 1 Centile ranges of volume across ages 60–85 years, for ventricle (left) and hippocampus (right). Recall region volumes
are normalised by the ICV value as they represent a percentage of volume within the intracranial cavity. Ranges up to the 100th
centile henceforth denote the empirical maximum volume for that region. Volume centiles; 75–100th from blue (0.75) to top
dotted line, 50–75th from green (0.25) to blue (0.75) line, 25–50th from red (0.25) to green (0.50) line and 15–25th from black
(0.15) to red (0.25) line. AD, Alzheimer’s disease; HC, healthy control; ICV, intracranial volume; MCI, mild cognitive impaired.
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Tables 1 and 2 present estimated rates of change as
well as the probabilities of diagnosis ordering for the
hippocampus and ventricles. Furthermore, the differ-
ence among HC and degeneration levels MCI and AD
shows the additional annual standardised age rate of
change from baseline. The increasing range of the cred-
ible intervals for each group as deterioration progresses
from HC to MCI to AD illustrates the stratiﬁed structure
of different sample sizes over groups in our data. The
box plots in ﬁgure 3 also demonstrate the general vari-
ability due to various diagnosis sample numbers.
Our BLME models also allow for probability state-
ments to be made, based on whether any of the slopes
are greater or smaller than a biologically meaningful
constant or threshold. Table 2 shows the posterior prob-
abilities of deterioration ordering for the three diagnosis
categories for ventricle and hippocampus volume, as
computed in equation (4). The large probabilities
support the sequential pattern of deterioration for both
regions.
Group comparisons are generally done via hypothesis
tests in a classical LME and do not allow for probability
Figure 2 Posterior densities of population mean estimates of linear deterioration rate for diagnosis (top plot): HC, MCI and AD,
for ventricle (left) and hippocampus volume (right) models. Dotted lines on bottom plots denote the means for each density,
whose values are shown in table 1. AD, Alzheimer’s disease; HC, healthy control; MCI, mild cognitive impaired.
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statements of group ordering or provide visualisation on
the distribution of the three groups which quantify the
variability in the varying group sizes. The results pre-
sented in table 1 support our hypothesis test results (full
analysis in online supplementary material), which show
that MCI and AD slopes were signiﬁcantly different from
baseline for the hippocampus model, whereas only AD
slope was signiﬁcant for the ventricle model, while both
classical and Bayesian results can be compared in tables
1 and 2 and the bottom of ﬁgure 2 can only be pro-
duced under the Bayesian framework.
R: How to identify individuals with high levels of
neurodegeneration?
The rates of deterioration (as measured by the rate of
change with respect to age) for the ventricle and hippo-
campus are in reverse order; large positive ventricle
slopes denote high atrophy, whereas low negative slopes
denote large hippocampus atrophy. Table 3 shows a
snippet of the participants ranked in order of their esti-
mated median posterior deterioration rate. The data
available in this study are highly unbalanced; nonethe-
less, all individuals are ranked despite 19 patients being
observed at a single time point only. This is due to the
‘borrowing strength’ aspect of mixed-effects models, in
that information across all time points contributes to the
estimation of the population trends.
Figure 3 shows clusterings based on HC, MCI and AD
participants, denoted by the blue, purple and red box
plots, respectively. This reﬂects the general order of
diagnosis rates of deterioration for the ventricle and
hippocampus volumes as shown in ﬁgure 2. However,
there are a few individuals who do not follow this
pattern, namely those in the small clustered group with
the positive estimated levels of atrophy in the hippocam-
pus model and participant ID 1122 in the ventricle
model. Participant IDs 1122 and 483 are 2 out of the 19
individuals who only had baseline measurements, so the
rate of deterioration was not observed, but it was still
estimated. The same analysis was conducted with a clas-
sical LME model and ﬁgure 3 and table 3 were repli-
cated (refer to the online supplementary material). We
found strong similarities with the ranking of the eight
converters of interest on hippocampus and ventricle
models.
There were 27 individuals who progressed from base-
line to a worse diagnosis. Eight individuals of interest
are those who progressed from HC to MCI and who had
at least three repeated observations recorded. Their esti-
mated deterioration rankings are shown in ﬁgure 3. The
majority of the eight converters in the hippocampus
model are scattered along the lower half of the ranking
of deterioration. This suggests that their linear rates of
hippocampus neurodegeneration are less than those of
the patients with AD. However, patient IDs 757, 232 and
471 were ranked approximately midway in this analysis,
suggesting that they are approaching hippocampus rates
of deterioration similar to AD, and out of the eight con-
verters, they are the ones most at risk.
Likewise, for the ventricle model at the top of
ﬁgure 3, patient ID 471 shows a ventricle rate of deteri-
oration strongly similar to the AD cohort. Further inves-
tigation of patient ID 471, such as family mental history
of other forms of dementia, stroke or other mental
illness, current cognitive status and other health-related
factors, may provide further insight as to why this indi-
vidual has an unusually high rate of ventricle deterior-
ation in comparison with the rest of the HC to MCI
converters.
Table 1 Posterior means for rates of deterioration across three diagnosis levels for ventricle and hippocampus volume (top),
and group differences among the three diagnosis levels (bottom), credible intervals for estimates in parentheses
Regions: units ICV volume/StndAge102
Parameter Ventricle Hippocampus
HC b3 0:56 (0:43; 0:63) 1:3 (1:8; 0:094)
MCI b3 þ b4 0:66 ð0:46; 0:88Þ 2:1 (2:9; 1:4)
AD b3 þ b5 0:96 (0:57; 1:2) 2:4 (3:7; 1:3)
Estimated difference of
volumetric change among
diagnosis groups
HC−MCI b4 0:094 (0:072; 0:23) 0:81 (1:7; 0:078)
HC−AD b5 0:38 (0:079; 0:70) 1:4 (2:5; 0:0011)
AD, Alzheimer’s disease; HC, healthy control; ICV, intracranial volume; MCI, mild cognitive impaired.
Table 2 Posterior probabilities showing comparisons
between HC, MCI and AD for ventricle and hippocampus
volume
Ventricle P(HC<MCI)=
P(0<b4)
P(MCI<AD)=
P(b4,b5)
0.980 0.991
Hippocampus P(AD<MCI)=
P(b5,b4)
P(MCI<HC)=
P(b5,0)
0.685 0.985
These results provide strong evidence regarding the order of
diagnosis levels, derived from the case study.
AD, Alzheimer’s disease; HC, healthy control; MCI, mild cognitive
impaired.
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Figure 4 shows the posterior distribution of ranks for
participant IDs 721 and 12 who converted from MCI to
AD at time point 4. Probabilities of these individuals
ranked in the lowest 15th quantile for the ventricle
volume are 0.75 and 0.46, respectively, for participant
IDs 721 and 12; likewise, for the hippocampus region,
these probabilities are 0.47 and 0.58. This same analysis
can be performed on any quantile range for any partici-
pants of interest. These probabilities show that these par-
ticipants are in the high neurodegeneration extreme.
These same analyses on the full data (over four time
points) result in probabilities of participant IDs 721 and
12 ranked in the top 15th quantile are 0.80 and 0.66 for
the ventricle and 0.54 and 0.69 for the hippocampus
regions. Refer to the online supplementary material for
posterior ranks distribution plots for all 27 converters.
Under the classical implementation of the model in
equation (3), the distribution of ranks for participants
cannot be derived. Once participant ranking is esti-
mated, no probability statements can be made to further
analyse individuals at the high or low ranking extremes
and compare, for example, the high and low 15th
Figure 3 Box plots of posterior distribution of random-effect values for participants in the AIBL study (N=260) for full data (four
time points). Ventricle (top) and hippocampus (bottom) rates of deterioration for each participant in the study. Since there are 157
HC, 34 MCI, 42 AD and 27 converters in this study, there is a higher uncertainty on the rate of deterioration of converters, MCI
and AD participants (hence longer box plots) as compared with the HC (narrower box plots). Eight individuals who converted
from HC to MCI throughout the study are highlighted in red with corresponding ID numbers. AD, Alzheimer’s disease; AIBL,
Australian Imaging Biomarker and Lifestyle Study of Ageing; HC, healthy control; MCI, mild cognitive impaired.
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quantile extremes. Refer to the online supplementary
material for the classical model results.
R: How do diagnosis trajectories vary over age?
The aim of these analyses is to show the relationship
between a volume centile, combined with results from
external sources, to predict region-speciﬁc diagnosis
changes over time. As described in the How do diagnosis
trajectories vary over age? section, we present here the
probability of a new individual diagnosed as either HC,
MCI or AD conditional on volume range and speciﬁed
age between 60 and 85 years.
Volume ranges, ~y, were the 75–100th, 50–75th, 25–
50th and 15–25th centiles, as shown in ﬁgure 1 in the
How do diagnosis trajectories vary over age? section.
Equation (5) established relationships P(HCj~y; age),
P(MCIj~y; age) and P(ADj~y; age), which consist of the
output from the BLME model stated in equation (3) in
conjunction with prevalence rates from Ward et al52 and
Refshauge and Kalisch.53
Uncertainty in the convergence trajectories of diagno-
sis levels is presented in terms of probabilities; hence,
no credible intervals can be estimated. However, there is
a Monte Carlo error associated with these estimates as
they are derived from a ﬁnite sample from the posterior
distribution. The ventricle and hippocampus models in
equation (3) were estimated independently B = 10 times;
hence, every computation to derive the probability tra-
jectories in this analysis was also estimated 10 times in
order to compute the Monte Carlo SE estimates. Let the
estimated quantity be denoted as u and sd be
the standard deviation; then a 95% interval for the
Monte Carlo SE is estimated as p^ + 1:96  sd
(u1; u2; . . . ; uB)
ﬃﬃﬃ
B
p
. As B ! 1, the Monte Carlo SE
tends to 0, and while practically B must be ﬁnite, our
narrow CIs in ﬁgure 5 suggest that our simulation
methods are adequate for our application.
The results in ﬁgure 5 show a large difference
between HC in contrast with MCI and AD diagnosis for
ages 60–75 across all ventricle volume quantiles. From
age 75 onwards, those individuals in the top centile
range (75–100th) show the quickest convergence of all
the diagnosis levels, who by age 85 show an approximate
equal probability (0.30 and 0.31) of being diagnosed as
MCI or AD and only a slightly higher chance (0.39) of
remaining HC. This contrasts those participants in the
lower ventricle volume range (15–25th), whose differ-
ence in diagnosis is vastly different towards the later
ages. By age 85, there is a mean estimated 0.60 probabil-
ity of remaining HC, a 0.27 probability of being classi-
ﬁed as MCI and an approximate 0.13 probability of AD
diagnosis.
Table 3 Ranking of individuals from largest to smallest in order of posterior expected rate of deterioration
(b3i ; b3i þ b4i; b3i þ b5i) slope for all 260 participants, with 95% credible intervals in parentheses
Ranking AIBL ID Diagnosis
Posterior mean rate of deterioration for
individuals (credible intervals)102
Ventricle 1 1122 AD 0:14 (1:1; 0:98)
2 68 HC 0:23 (0:19; 0:64)
3 771 HC 0:28 (0:13; 0:66)
4 814 HC 0:29 (0:054; 0:064)
5 698 HC 0:29 (0:011; 0:60)
… … … …
256 1032 AD 1:6 (0:55; 2:7)
257 102 AD 1:6 (0:81; 2:4)
258 10 AD 1:7 (0:78; 2:7)
259 658 AD 1:7 (0:94; 2:5)
260 1102 AD 2:3 (1:5; 3:2)
Hippocampus 1 10 AD 9:3 (16;  3:7)
2 12 AD 6:1 (9:9;  2:4)
3 1135 AD 5:7 (1:1 1:0)
4 398 AD 5:6 (9:5;  1:7)
5 19 AD 5:4 (9:8;  1:7)
… … … …
256 156 HC 0:02 (1:5; 1:8)
257 62 HC 0:41 (0:95; 1:8)
258 80 HC 1:0 (0:54; 2:7)
259 483 MCI 1:2 (1:9; 4:6)
260 1122 AD 1:5 (1:5; 4:9)
A snippet of the table shows the first and last five individuals, for ventricle and hippocampus volumes. Diagnosis levels: HC, MCI, AD and
converter (either from HC to MCI, HC to AD or MCI to AD), to identify the 27 individuals who changed diagnosis throughout the study, as
seen in figure 3.
AD, Alzheimer’s disease; AIBL, Australian Imaging Biomarker and Lifestyle Study of Ageing; HC, healthy control; MCI, mild cognitive impaired.
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The hippocampus model results for this analysis are
shown at the bottom of ﬁgure 5. Between the ages 60–
70, there is very little difference across the diagnosis pat-
terns, suggesting that individuals whose hippocampus
volume lies above the 15th centile have an approxi-
mately equal risk of HC, MCI or AD diagnosis. From age
70 onwards, a noticeable difference in diagnosis trajec-
tories is seen across all volume regions, 5 years earlier
than the ventricle volume results. This is supported by a
large body of literature,5 31 57–60 as the hippocampus is
affected at an early stage of development of AD com-
pared with other brain regions. Since a low hippocam-
pus volume denotes high atrophy, individuals who fall in
the lower range volumes, 15–25th centile, are most at
risk of proceeding onto AD. Individuals in the lower
hippocampus volume range, at age 85, have an approxi-
mate equal chance of HC, MCI or AD, as shown in
ﬁgure 5.
Diagnosis trajectories over groups, male, female,
APOE ε4 carriers and non-carriers, were also investi-
gated for the hippocampus and ventricle regions using
the model equation (3). We assumed the same preva-
lence rates within the population, for example,
P(MCIjage)¼ PðMCIjage; femaleÞ; hence, the same
broad prevalence rates from Ward et al52 and Refshauge
and Kalisch 53 were used. Very little difference in the
probable disease trajectory across all groups between
ages 60 and 85 was observed (refer to the online
supplementary material for plots). APOE 14 has been
associated with an increased likelihood of developing
AD.61–63 Gender differences regarding the prevalence of
AD have also been studied.64 65 Since the BLME models
and inference derivation presented in this paper are the
ﬁrst of their kind, the objective of this analysis is to
demonstrate probable diagnosis trajectories conditional
on very broad, non-group-speciﬁc prevalence rates.
Future models which account for APOE ε4, gender and
other factors will use group-speciﬁc prevalence rates.
However, to derive the same inference, this would
require group-speciﬁc prevalence rates across ages 60–
85, which are difﬁcult to attain from the literature.
Our results support those presented in Holland et al,15
whereby diagnosis trajectories for neurodegenerated
individuals (ie, those with a very low hippocampus and
high ventricle volume) converge at the highest age
group, in general over the age of 85. In particular, our
results support those presented in Jack et al30 for a prob-
abilistic trajectory of β amyloid negative and
neurodegeneration-positive participants. To make our
results comparable to those from Jack et al,30 HC partici-
pants whose hippocampus volume is less than the 50th
centile are deﬁned as neurodegeneration positive. While
both methods present trajectories for neurodegenera-
tion of participants over age, the BLME models pre-
sented here primarily estimate the rate of volumetric
change for the ventricle and hippocampus regions.
There are many other inferences that can be deduced
from a combination of tapping into the vast wealth of
AD research,5 66 coupled with the present study analysis.
The results presented here are some of the advantages
of modelling neurodegeneration through mixed-effects
models in the Bayesian framework.
DISCUSSION
In this research, we extended the level of insight com-
monly derived by LME models applied to longitudinal
neuroimaging data into three key areas based on a
BLME model on the ventricle and hippocampus ICV
normalised volumes. We propose that a Bayesian
approach for longitudinal neuroimaging modelling has
merit for providing further understanding of brain
atrophy over time. These views were demonstrated using
an application of BLME models applied to a longitu-
dinal AIBL study, which were compared with the clas-
sical alternative of LME models.
Comparisons of a volumetric rate of change of
diagnosis-level trajectories were compared for HC, MCI
Figure 4 Posterior distribution of ranks for MCI to AD converters ID 721, 365 and 12, for ventricle (top) and hippocampus
(bottom) ICV volume models. These density rankings were derived with observations from time points 1–3. AD, Alzheimer’s
disease; ICV, intracranial volume; MCI, mild cognitive impaired.
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Figure 5 Probability curves
show the posterior probability of
HC, MCI or AD diagnosis for the
ventricle (top) and hippocampus
(bottom) models, while the 95%
interval denotes the Monte Carlo
error based on several
simulations of the BLME models.
Total volume is divided into four
centile volume ranges, as shown
in figure 1. Centiles: 75–100th,
50–75th, 25–50th and 15–25th.
AD, Alzheimer’s disease; BLME,
Bayesian linear mixed-effects;
HC, healthy control; MCI, mild
cognitive impaired.
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and AD participants, with an estimated probability >0.65
on the order of disease pathology, while credible inter-
vals for the parameters support results from the hypoth-
esis test on a classical LME; under this framework, the
probability of disease pathology order is not straightfor-
ward to compute. Ranking of converters with respect to
the study cohort and diagnosis trajectories over age
based on volumetric quantiles are the ﬁrst BLME ana-
lysis of their kind applied to longitudinal neuroimaging
data. This analysis identiﬁed HC to MCI converters most
at risk of AD-like rate of deterioration and posterior
rank distributions provided probabilities on individuals
of interest in the worst 15th centile rank for both
regions. The predictive capability of future converters
can be derived from these BLME models, as individuals
with high neurodegeneration estimates would rank at
the extremes in comparison with the remainder of the
cohort. The uncertainty of their rank values among a
speciﬁed quantile is expressed in terms of probabilities,
and individuals with a high probability of ranking at
extreme levels of neurodegeneration may be indicative
of their progressive pathway to further stages of demen-
tia. While classical methods were also able to rank parti-
cipants in order of estimated volumetric rate of change,
they do not allow for further estimation of the highest
ranked individuals and the uncertainty in their position.
However, to rigorously validate this analysis, a richer data
set with more repeated measures and converters over all
categories (HC to MCI or AD and MCI to AD) observed
at various ages is required. Furthermore, the diagnosis
trajectories for each volume region identiﬁed critical
points in time both ventricle and hippocampus degener-
ation from which participants are most likely to show
greater deterioration rates. Alternatively, a similar ana-
lysis can also be used to compare diagnosis trajectories
of different longitudinal neuroimaging population
studies, such as the ADNI.
Additional analysis regarding group comparisons can
be made. For example, similar probabilities for an esti-
mated population mean in comparison to a biologically
meaningful constant could also be inferred. An exten-
sion to our second analysis to allow population studies to
focus on speciﬁc participants of interest and monitor
their progression rate throughout follow-ups could assist
health professionals in making informed choices with
regard to patient care. Alternatively, HC to AD conver-
ters may also be further analysed and ranked with
respect to the cohort, to provide further clues as to why
these individuals deteriorated so quickly compared with
their slower converter counterparts. It is worthwhile to
note that these inference extensions would not have
been possible had we not ﬁrst attempted the research
methods presented in this paper.
A sensitivity analysis with respect to the prior informa-
tion used in our analysis was conducted on the ventricle
and hippocampus models. This entailed rerunning the
MCMC sampling technique for each model based on
various speciﬁcations of the prior information. The
subsequent posterior summaries did not vary consider-
ably based on different prior information. Hence, we
conjecture that the results are relatively robust to the
priors speciﬁed in this work. Furthermore, two LOOCV
methods were applied to assess the models’ predictive
capability.
Despite every precaution taken to provide robust and
reliable conclusions from the BLME models, several
authors7 14 have noted the limitations and disadvantages
of Bayesian statistics applied to longitudinal neuroima-
ging analysis. In particular, drawbacks of Bayesian statistics
in the neuroimaging context are discussed at length in
Grunkemeier and Payne.67 These include subjective infor-
mation that can be incorporated in the BLME model spe-
ciﬁcation, in the way in which the prior is speciﬁed.
Moreover, computational intensity is often far greater in
the Bayesian framework than numerical methods
employed in a frequentist analysis. In this paper, we incor-
porated vague priors which are semiconjugate, as we
assumed no prior knowledge of the study analysed; the
prior speciﬁcation were a standard choice as suggested in
Gelman and Hill.23 The additional computational time
taken to run both models speciﬁed in the BLME in the
context of the case study section was not excessive and
was deemed to be worth the additional insight given. We
suggest that more complex models and future extensions
to the methods presented in this paper may result in an
increase in computational time, and this will be a factor
to consider in future BMLE models.
Extensions to the BLME models presented in this
paper include the addition of more covariates to
account for trends and variability sources present in
gender, genetic factors and additional demographic
characteristics which are a few of the key factors known
to affect AD onset and disease progression.
Furthermore, since the Bayesian framework is ideal for
handling complex models such as generalised linear
mixed models41 68 and spatiotemporal interactions,69 70
extensions of this nature will allow for modelling bio-
marker deterioration rates of multiple brain regions sim-
ultaneously over time.
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